Sumitomo Pharma Co., Ltd.
Formulation of Boost 2028 ― Accelerating the Strong Sumitomo Pharma ―
Sumitomo Pharma has formulated the growth strategy 'Boost 2028' covering fiscal years 2026 to 2028, aiming for over 350 billion yen in sales from Orgovix and Gemtesa, ROE above 10%, and equity ratio over 50% by fiscal 2028.
Key Figures
- Core Operating Income for Fiscal 2025: 107 billion yen (record high profit, expected to achieve Reboot 2027 target ahead of schedule)
- Fiscal 2028 Sales Target (Orgovix & Gemtesa): Over 350 billion yen
- Cumulative R&D Expenses (Fiscal 2026-2028): Over 180 billion yen (including regenerative and cell pharmaceutical business)
AI要約
Background of Formulating Boost 2028
After a deterioration in performance in fiscal 2023, Sumitomo Pharma implemented structural reforms and achieved a V-shaped recovery in fiscal 2024. Since the targets of 'Reboot 2027,' formulated in May 2025, are expected to be achieved ahead of schedule, the Board of Directors approved a new growth strategy, 'Boost 2028,' for fiscal years 2026 to 2028. The company aims to continue strict cost management and accelerate growth.
Key KPIs and Initiatives of Boost 2028
Aiming for sales exceeding 350 billion yen from Orgovix and Gemtesa, ROE above 10%, and equity ratio over 50% by fiscal 2028, the company will allocate cumulative R&D expenses exceeding 180 billion yen, including regenerative and cell pharmaceutical businesses. Priority is placed on maximizing the value of focus products and launching two new cancer drugs (enzomenib and nuvisertib), while strengthening R&D foundations in hematologic tumors and neurodegenerative fields. Early dividend resumption is also targeted as shareholder return.
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
